Gorelov Ai

ORCID: 0000-0002-2858-5317
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Urological Disorders and Treatments
  • Ureteral procedures and complications
  • Salmonella and Campylobacter epidemiology
  • Renal cell carcinoma treatment
  • Tissue Engineering and Regenerative Medicine
  • Urinary Tract Infections Management
  • Urinary Bladder and Prostate Research
  • Digestive system and related health
  • Reproductive tract infections research
  • Diagnosis and treatment of tuberculosis
  • Genital Health and Disease
  • Amoebic Infections and Treatments
  • Urinary and Genital Oncology Studies
  • Cancer Diagnosis and Treatment
  • Cancer Research and Treatments
  • Urologic and reproductive health conditions
  • Probiotics and Fermented Foods
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • Multiple and Secondary Primary Cancers
  • Cancer Immunotherapy and Biomarkers
  • Hepatitis B Virus Studies
  • Pelvic floor disorders treatments
  • Cervical Cancer and HPV Research

St Petersburg University
2008-2024

North-Western State Medical University named after I.I. Mechnikov
2020

Clinical Hospital No 122 named after. L.G.Sokolova
2019

Karolinska Institutet
2016

Centre International de Recherche sur le Cancer
2016

Radboud University Nijmegen
2009

Radboud University Medical Center
2009

Centralny Szpital Kliniczny
2009

Loyola University Medical Center
2008

Research Institute of Obstetrics and Gynecology named after D.O. Ott
2005

We tested prostatic secretions from men with and without prostate cancer (13 cases 13 matched controls) or prostatitis (18 18 metagenomic sequencing. A large number (>200) of viral reads was only detected among four (1 patient each positive for Merkel cell polyomavirus, JC polyomavirus Human Papillomavirus types 89 40, respectively). Lower numbers a variety viruses were in all groups. Our knowledge the biology may be furthered by fact that DNA are commonly shed can readily sequencing...

10.1038/srep25235 article EN cc-by Scientific Reports 2016-04-28

3009 Background: Vitespen (formerly HSPPC-96) is a novel, autologous, heat shock protein (gp96)-peptide complex vaccine. The survival registry investigating long-term efficacy of vitespen in renal cell carcinoma (RCC) patients at high risk for recurrence postnephrectomy. Methods: Eligible were enrolled and active Antigenics’ C-100–12 phase III protocol, with last status alive study end. Patients randomized (1:1, vs. observation) had AJCC stage I (T1b), II (≥5 cm; Fuhrman grade 3/4), III, or...

10.1200/jco.2009.27.15_suppl.3009 article EN Journal of Clinical Oncology 2009-05-20

Abstract Reconstructive surgery for urethral defects employing tissue‐engineered scaffolds represents an alternative treatment urethroplasty. The aim of this study was to compare the therapeutic efficacy bilayer poly‐D,L‐lactide/poly‐ε‐caprolactone (PL‐PC) scaffold seeded with allogenic mesenchymal stem cells (MSCs) urethra reconstruction in a rabbit model conventional urethroplasty autologous buccal mucosa graft (BG). inner layer based on poly‐D,L‐lactic acid (PL) MSCs, while outer layer,...

10.1002/jbm.b.34453 article EN Journal of Biomedical Materials Research Part B Applied Biomaterials 2019-08-01

Bladder cancer is a heterogeneous group of tumor lesions the bladder, mainly represented by two types malignant epithelial tumors - muscle-invasive urothelial bladder (MIUBC) and non-muscle-invasive (NMIUBC). Due to different molecular genetic profile various carcinomas (the development NMIUBC occurs along path activation oncogenes (FGFR3, RAS kinase genes), MIUBC damage chromatin remodeling genes, inactivation suppressor genes (TP53, RB1, PTEN), an attractive model for studies immunological...

10.37539/231128.2023.83.11.018 article EN 2024-01-23

4586 Background: Paclitaxel Injectable Emulsion (PIE; TOCOSOL™ Paclitaxel) is a convenient, ready-to-use, Cremophor®-free unmodified paclitaxel product administered over 15 min. Methods: As part of Phase 2A program, multicenter study second line PIE was performed in taxane-naïve patients (pts) with metastatic or locally advanced, unresectable recurrent TCC who progressed after cisplatin (cis)-based therapy. given IV min weekly to dose cohorts 80, 100, and 120 mg/m2. Results: 27 pts were...

10.1200/jco.2004.22.90140.4586 article EN Journal of Clinical Oncology 2004-07-15

Coronavirus pandemic significantly changed our lives, leading to long-lasting medical, social, economic, psychological consequences. Currently, when the COVID-19 morbidity growth is less galloping, more important are issues of prognosis, rehabilitation, immunity stability, risk recurrent infection etc. An increased incidence stress-induced somatic and mental diseases envisaged. Among them, sleep disorders appear be significant can result from various reasons: change in habitual life style,...

10.18705/1607-419x-2020-26-4-468-484 article EN Arterial’naya Gipertenziya (Arterial Hypertension) 2020-08-28

Introduction. In order to exclude the difficulties arising in course of traditional surgical interventions scope substitutional urethroplasty, recent years, alternative materials have been developed using tissue engineering. This study is devoted development new tissue-engineered constructions for urethroplasty cells different origins and biopolymers, which an urgent problem modern medicine.
 Aim. Experimental provision a rationale possibility replace urethral defects.
 Methods...

10.17816/uroved46031 article EN Urology reports (St - Petersburg) 2020-10-26

Fluoroquinolones are recommended in the therapy of chronic prostatitis. Chlamydia trachomatis is one possible aetiological agents However, little known about chlamydia survival presence fluoroquinolones patients with prostatitis syndrome. For first time, vitro lomefloxacin (LOMX) (mostly treatment prostatitis) versus levofloxacin (LVFX) (recommended against infection) examined and analysed 33 chlamydia-infected syndrome this study. Antichlamydial activity LOMX C. was found to be more...

10.1111/j.1439-0272.2005.00654.x article EN Andrologia 2005-06-01
Coming Soon ...